Skip to main content
 

2014 Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
06/27/14Idera Pharmaceuticals to be Added to the Russell 3000® and Russell 2000® Indexes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 27, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that it will be added to the Russell 3000® and Russell 2000® Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 27, 2014, according to a preliminary list ... 
Printer Friendly Version
06/17/14Idera Pharmaceuticals to Participate in a Panel Discussion at the Piper Jaffray GenomeRx Symposium
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that Sudhir Agrawal, D. Phil., Chief Executive Officer, will participate in a panel discussion entitled “RNA/DNA: Getting It Where You Need It” at the Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014. The panel ... 
Printer Friendly Version
06/13/14Idera Pharmaceuticals to Present at the Nucleic Acid Summit 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 13, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today announced that Walter Strapps, Ph.D., Executive Director of RNA Therapeutics, will present at the Nucleic Acid Summit 2014 in San Diego, California on Thursday, June 19, 2014 at 4:15 p.m. PDT. The title of Dr. Strapps’ presentation is "Gene Silencing... 
Printer Friendly Version
05/28/14Idera Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today announced that Company management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 8:30 a.m. EDT in New York City. A live audio webcast of the presentation will be available in the Investors ... 
Printer Friendly Version
05/13/14Idera Pharmaceuticals Reports First Quarter 2014 Financial Results and Provides Update on Key Programs and Business Strategy
- Strengthened leadership team in development and commercialization for orphan drugs – - Initiated clinical development in Waldenström’s and DLBCL patients - - Presented promising preclinical data in genetically defined forms of B-cell lymphoma - - Entered into collaboration with Abbott for companion diagnostic - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical sta... 
Printer Friendly Version
05/08/14Idera Announces Agreement with Abbott to Develop a Companion Diagnostic for IMO-8400 in Genetically Defined Forms of B-cell Lymphoma
- IMO-8400 is in clinical development for the potential treatment of two genetically defined forms of B-cell lymphoma characterized by the presence of the oncogenic mutation MYD88 L265P – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotechnology company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced today tha... 
Printer Friendly Version
05/06/14Idera Pharmaceuticals to Host Conference Call and Webcast to Report First Quarter 2014 Financial Results and Provide a Detailed Pipeline Review
- Company to Review Pipeline of Orphan Therapeutic Candidates, Business Strategy and Recent Highlights - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced that the Company will host a conference call and live audio webcast with an accompa... 
Printer Friendly Version
05/05/14Idera Expands Management Team with Three Key Hires
- Expansion Supports Rapid Development of Novel Drug Pipeline in Oncology and Orphan Diseases - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced the addition of three new management team members to support the Company’s progress in its d... 
Printer Friendly Version
04/07/14Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation
- Data supports TLR antagonism as potential therapeutic approach for genetically defined forms of B-cell lymphoma – - IMO-8400 in Phase 1/2 trial for Waldenström’s macroglobulinemia – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 7, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today presented new preclinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L26... 
Printer Friendly Version
03/28/14Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
Trial meets primary objective of demonstrating safety and tolerability over 12-week treatment period IMO-8400 also demonstrates clinical proof-of-concept in psoriasis CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. Th... 
Printer Friendly Version
03/13/14Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update
- Clinical advancements in autoimmune diseases and genetically defined forms of B-cell lymphoma - - Details announced for planned clinical development of IMO-8400 in polymyositis and dermatomyositis – - Plans announced to identify drug candidates from its gene silencing oligonucleotide platform - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceuti... 
Printer Friendly Version
03/13/14Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases
- Company to initiate clinical development of IMO-8400 in polymyositis and dermatomyositis in first half of 2014 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today announced that it plans to initiate clinical development... 
Printer Friendly Version
03/12/14Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 12, 2014-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments’ Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014. Founded in 2000, Baker Brothers Investment... 
Printer Friendly Version
03/06/14Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial res... 
Printer Friendly Version
02/26/14Idera to Present at the Cowen & Co. 34th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley ... 
Printer Friendly Version
02/18/14Idera to Present at the 2014 RBC Capital Markets’ Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 18, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hote... 
Printer Friendly Version
02/10/14Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant, which is the per share public ... 
Printer Friendly Version
02/06/14Idera to Present at 16th Annual BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. ... 
Printer Friendly Version
02/05/14Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price ... 
Printer Friendly Version
02/04/14Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and th... 
Printer Friendly Version
01/22/14Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2014-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced the publication of a study supporting the potential role of the suppression of Toll-like-receptors (TLRs) 7, 8, and 9 in the treatment of psoriasis. The data were published ... 
Printer Friendly Version
01/09/14Idera Expands Leadership Team and Strengthens Clinical Development Expertise in Oncology and Orphan Diseases
Chief Medical Officer Lou Brenner, MD, and New Board Member Mark Goldberg, MD, to help guide clinical development strategy and execution CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2014-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that it has strengthened its clin... 
Printer Friendly Version

Contact

Please direct all general questions regarding Idera to:

Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge, MA 02139

617-679-5500 tel
617-679-5592 fax

info@iderapharma.com